D’Alterio et al. found that CXCR4 inhibition using plerixafor significantly reduced metastasis by blocking stromal cell recruitment and p38 MAPK activation, impairing tumor cell survival (D’Alterio et al., 2012). The gene discussed is CXCR4; the disease is neoplasm.